🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER 2 Negative Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites📍 La Jolla📍 Los Angeles📍 Port Saint Lucie Regor Pharmaceuticals Inc. · Tests: RGT-419B, RGT-419B in combination with hormonal therapy Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer NCT07180160Phase 21 site📍 Shanghai Wenjin Yin · Tests: QL1706, CDK4/6 inhibitor, Fulvestrant Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC NCT06500208Phase 21 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. NCT07227233Phase 21 site📍 La Jolla University of California, San Diego · Tests: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physicia… Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer NCT07427394Phase 26 sites📍 St Louis📍 East Providence📍 Nashville AstraZeneca · Tests: Camizestrant, Atirmociclib Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer NCT06106477NA1 site📍 Milwaukee Medical College of Wisconsin · Tests: Intermittent Fasting Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer NCT07180056n/a1 site📍 Shanghai Wenjin Yin · Tests: CDK4/6 inhibitor Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer NCT07137416Phase 12 sites📍 Boston📍 St Louis National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy NCT02945579NA8 sites📍 Gilbert📍 Jacksonville📍 Honolulu M.D. Anderson Cancer Center · Tests: Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast I… TCb vs EC-T in High Risk ER+/HER2- Breast Cancer NCT05901428Phase 31 site📍 Shanghai Fudan University · Tests: Docetaxel, Carboplatin, Epirubicin, Cyclophosphamide A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer NCT06369285Phase 253 sites📍 Birmingham📍 Phoenix📍 Beverly Hills Puma Biotechnology, Inc. · Tests: Alisertib, Endocrine therapy S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer NCT03723928NA723 sites📍 Anchorage📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Ques… VS-6766+Abema+Fulv in Met HR+/HER- BC NCT05608252Phase 1, Phase 23 sites📍 Boston📍 Boston📍 Boston Adrienne G. Waks · Tests: VS-6766, Abemaciclib, Fulvestrant Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer NCT06062498Phase 23 sites📍 Chicago📍 Chicago📍 Chicago Northwestern University · Tests: elacestrant, palbociclib, abemaciclib, ribociclib A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery NCT06127979NA1 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: blood draw NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline NCT06452394Phase 28 sites📍 Sankt Gallen📍 Genolier📍 Winterthur Swiss Cancer Institute · Tests: Doxycyclin Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients NCT04836156Phase 1, Phase 21 site📍 Beijing Peking University People's Hospital · Tests: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer, neoadjuvant ch… Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks NCT05212454Phase 31 site📍 Hanzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Capecitabine BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer NCT06756932Phase 114 sites📍 Iowa City📍 Houston📍 Seattle BeOne Medicines · Tests: BGB-21447, Fulvestrant, BGB-43395 Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites📍 Los Angeles📍 Grand Rapids📍 New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion … · Tests: GTAEXS617, SoC Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer NCT06462092Phase 1, Phase 21 site📍 Huizhou Guangzhou Medical University · Tests: Sacituzumab Govitecan, Pemetrexed Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites📍 Phoenix📍 Irvine📍 San Diego RayzeBio, Inc. · Tests: RYZ101, Standard of Care Endocrine Therapy A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer NCT05187832Phase 11 site📍 Nashville Kind Pharmaceuticals LLC · Tests: AND019 PO QD RADIANT: Pre-op Radiation With Abemaciclib and Letrozole NCT06139107Phase 14 sites📍 Belleville📍 Livingston📍 New Brunswick Mridula George, MD · Tests: Abemaciclib, Letrozole Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study NCT07546695n/a1 site📍 Basel University Hospital, Basel, Switzerland · Tests: Data Collection from medical records of from an already existing database "ONCOLOGICAL BREAST SURGERY DATABASE OF … A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites📍 Beijing📍 Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 NCT06084481Phase 154 sites📍 Duarte📍 San Francisco📍 Aurora AbbVie · Tests: ABBV-400, Itraconazole (ITZ), Bevacizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy